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Abstract In the subgranular zone (SGZ) of the hippocampus,
neurogenesis persists throughout life and is upregulated fol-
lowing ischemia. Accumulating evidence suggests that en-
hanced neurogenesis stimulated by ischemic injury contrib-
utes to recovery after stroke. However, the mechanisms un-
derlying the upregulation of neurogenesis are unclear. We
have demonstrated that a neuropeptide, pituitary adenylate
cyclase-activating polypeptide (PACAP), exerts a wide range
of effects on neural stem cells (NSCs) during neural develop-
ment. Here, we examined the effects of endogenous and ex-
ogenous PACAP in adult NSCs of the SGZ. Immunostaining
showed expression of the PACAP receptor PAC1R in nestin-
positive NSCs of adult naive mice. PACAP injection into the
lateral ventricle increased bromodeoxyuridine (BrdU)-posi-
tive proliferative cells in the SGZ. These data suggest that
PACAP promoted the proliferation of NSCs. In global ische-
mia model mice, the number of BrdU-positive cells was in-
creased in wild-type mice but not in PACAP heterozygous
knockout mice. The BrdU-positive cells that increased in
number after ischemia were immunopositive for SOX2, a
marker of NSCs, and differentiated into NeuN-positive mature
neurons at 4 weeks after ischemia. These findings suggest that
PACAP contributes to the proliferation of NSCs and may be
associated with recovery after brain injury.
Keywords Pituitary adenylate cyclase-activating
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Introduction
Pituitary adenylate cyclase-activating polypeptide (PACAP) is
a neuropeptide that was first isolated from the ovine hypothal-
amus based on its ability to stimulate adenylate cyclase activ-
ity in pituitary cells (Miyata et al. 1989). This neuropeptide
belongs to the secretin/glucagon/vasoactive intestinal peptide
(VIP) superfamily and exists as two biologically active forms,
PACAP38 and PACAP27 (Kimura et al. 1990). Three
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receptors mediate the actions of PACAP: PAC1R, VPAC1R,
and VPAC2R. Among these receptors, PACAP binds to
PAC1R specifically with high affinity, while VIP and
PACAP bind to VPAC1R or VPAC2R with similar affinities
(Arimura 1998). These receptors are widely distributed in the
body (Vaudry et al. 2009). PACAP exerts a wide range of
effects on different cell types in the brain as early as fetal stage
(Watanabe et al. 2007; Zhou et al. 1999). PACAP and its
receptors are expressed in germinative neuroepithelia, sug-
gesting that PACAP may be involved in neurogenesis
(Sheward et al. 1998). PACAP has been shown to regulate
cell fate in various developmental contexts, in a manner de-
pendent on dose, region, signaling, and receptor subtype
(Jaworski and Proctor 2000; Waschek et al. 1998). Recent
studies suggest the contribution of PACAP to proliferation
and differentiation of neural stem cells (NSCs) (Nakamachi
et al. 2011).
It is well known that NSCs exist not only in the de-
veloping nervous system but also in the adult nervous
system of mammals. The locations of NSCs are limited
in the adult, including the subgranular zone (SGZ) of the
hippocampus and the subventricular zone (SVZ) of the
lateral ventricle. In particular, adult hippocampal
neurogenesis has garnered great interest because of its
potential to influence learning and memory (Deng et al.
2010). Multipotent NSCs are located within the SGZ,
which are capable of repeated self-renewal and the gen-
eration of both neurons and astrocytes (Bonaguidi et al.
2011). Continuous adult hippocampal neurogenesis func-
tions in cognition and mood regulation, and studies sug-
gest that dysfunction of hippocampal neurogenesis cause
learning and behavioral impairments (Christian et al.
2014). Recent studies also suggest that hippocampal
neurogenesis is responsible for some aspects of recovery
following brain injury (Yu et al. 2016). Increased hippo-
campal neurogenesis is known to occur following cere-
bral ischemia (Liu et al. 1998). Several genetic and en-
vironmental factors have shown to modulate cell fate of
NSCs (Kempermann et al. 2015); however, the entire
mechanisms that regulate neurogenesis after neural dam-
age are still unclear.
Previous studies have evaluated the role of PACAP in
NSCs during development of the nervous system.
PACAP and PAC1R are known to be expressed in em-
bryonic and postnatal brains of rodents (Watanabe et al.
2007). During the early stages of neural development,
PAC1R messenger RNA (mRNA) expression is observed
in the ventricular zone throughout the neuraxis. After
birth, its expression in central nervous system is predom-
inantly limited to the SVZ, olfactory bulb, hippocampus,
and cerebellum. Many reports indicate that PACAP plays
crucial roles in the proliferation and differentiation of
neurons, astrocytes, and oligodendrocytes (Nakamachi
et al. 2011; Watanabe et al. 2007). However, the involve-
ment of PACAP in adult neurogenesis is not clearly
understood.
PACAP is well known to be a promising neuroprotec-
tive peptide. The protective effects of PACAP have been
shown in various models of brain injuries, including ce-
rebral ischemia, Parkinson’s disease, trauma, and nerve
transections (Lee and Seo 2014; Reglodi et al. 2011;
Reglodi et al. 2015). The upregulation of PACAP follow-
ing several types of nerve injuries indicates that endoge-
nous PACAP plays a role in the post-traumatic recovery
of the nervous system (Somogyvári-Vigh and Reglodi
2004). About stroke, a number of papers have reported
that PACAP suppressed neuronal cell death or decreased
infarct volume after global and focal ischemia in rodents
(Dohi et al. 2002; Ohtaki et al. 2006; Ohtaki et al. 2008a;
Reglodi et al. 2000; Uchida et al. 1996). Interestingly,
recent study reported that the delivery of PACAP in the
vicinity of the infarct zone 3 days poststroke improved
funct ional recovery by inducing M2 microgl ia /
macrophage polarization (Brifault et al. 2015). This study
suggested that PACAP could also play an important role
in the modulation of inflammation after stroke. As recent
studies reported that inflammation after neural disease is
necessary for neurogenesis (Belarbi and Rosi 2013),
PACAP could also be involved in the proliferation and
differentiation of NSCs after brain damage. Though the
neuroprotective effect of PACAP is well established, its
role in neurogenesis after stroke is still unclear.
In the present study, we hypothesized that PACAP is in-
volved in hippocampal neurogenesis of adult mice. Therefore,
we examined the neurogenetic effect of PACAP using intra-
ventricular PACAP treatment and a global ischemia model in
PACAP-deficient mice.
Materials and Methods
Animals
PACAP-deficient mice have been reported previously
(Hashimoto et al. 2001). The experiment comparing the ef-
fects of endogenous PACAP in PACAP-deficient and wild-
type mice was carried out using littermates (PACAP+/+ and
+/− mice) from the breeding of PACAP+/− mice. Other ex-
periments using wild-type mice were carried out using
C57BL/6 wild-type mice obtained from Charles River Japan
(Tokyo, Japan). Male mice were used in all experiments.
Animal care and all experimental procedures involving animal
use were approved by the Institutional Animal Care and Use
Committee of Showa University. Mice were housed in a con-
trolled environment (23 °C, 12/12-h light/dark cycle) and pro-
vided with free access to water and standard rodent chow.
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Mouse NSC Culture
Primary cell culture of NSCs was essentially carried out as
described previously (Watanabe et al. 2013). Briefly, telen-
cephalons were prepared from embryos (embryonic day
14.5) of ICR mice and gently dissociated by pipetting. The
dissociated cells, which included neural progenitor cells, were
seeded onto a culture dish precoated with 15 μg/ml poly-L-
ornithine and 1 μg/ml fibronectin (Sigma-Aldrich, St. Louis,
MO). The cells were cultured in Dulbecco’s modified Eagle’s
medium/F12 (Life Technologies, Carlsbad, CA) containing
25 μg/ml insulin, 100 μg/ml human apotransferrin, 20 nM
progesterone, 100 μM putrescine, 30 nM sodium selenite,
antibiotic antimycotic solution (Sigma-Aldrich), and 10 ng/
ml recombinant human basic fibroblast growth factor (R&D
Systems, Minneapolis, MN) for 4 days.
PACAP and Vehicle Treatments
Wild-type C57/BL6 male mice were anesthetized with
sevoflurane. A stainless steel cannula was inserted into
the right lateral ventricle at the position of 0.5 mm pos-
terior, 1.0 mm lateral, 2.2 mm ventral from bregma and
fixed with dental cement. At 1 week after cannulation,
PACAP38 (480 pmol/kg/day, Peptide Institute, Osaka,
Japan) dissolved in 0.1 % bovine serum albumin/saline
or the vehicle only were continuously injected by an
Alzet micro-osmotic pump (Model 1007D, 0.5 μl/h,
Alzet, Cupertino, CA) until day 7.
Common Carotid Artery Occlusion and Reperfusion
Global ischemia was induced by common carotid artery oc-
clusion and reperfusion as described previously (Nakamachi
et al. 2013; Ohtaki et al. 2008b). Wild-type and PACAP+/−
mice were anesthetized with sevoflurane. Anesthesia was
maintained with 2 % sevoflurane in NO2/O2 (7:3) via a
facemask. A midline incision was made, and then, both com-
mon carotid arteries were exposed. Both arteries were isolated
and occluded with artery clips. After 12 min, the clips were
removed for reperfusion and the neck incision was sutured.
The animals were kept in an incubator room at 37 °C and then
moved to room temperature.
BrdU Treatment
For bromodeoxyuridine (BrdU) staining and cell counts,
BrdU (Sigma-Aldrich) was injected prior to sacrifice.
Schematic experimental schedule is described in
Supplemental Fig. 1. In the experiment assessing the effects
of exogenous PACAP, BrdU was injected intraperitoneally
starting from 14 h prior to sacrifice at a dose of 50 mg/kg
every 2 h for a total of six times. Animals were sacrificed at
2 h after the last BrdU injection (Supplemental Fig. 1a). In the
experiment assessing the effects of endogenous PACAP, BrdU
was injected intraperitoneally at 3 h prior to sacrifice at a dose
of 300 mg/kg. Animals were sacrificed on days 0, 1, 3, 7, 14,
28, and 56 in this experiment (Supplemental Fig. 1b).
Histology
Animals were deeply anesthetized by intraperitoneal in-
jection of sodium pentobarbital (50 mg/kg) and then per-
fused transcardially with 0.9 % saline followed by 2 %
paraformaldehyde (PFA) in 50 mM phosphate buffer.
Brains were removed and postfixed in fixative solution
overnight, followed by immersion in 0.1 M phosphate
buffer containing 20 % sucrose for 2 days. Sections were
prepared as frozen sections for immunohistochemistry
and immunocytochemistry. Brains were cut from 2 mm
anterior to 3 mm posterior to the bregma, embedded in
O.C.T. compound (Sakura Finetech, Tokyo, Japan), and
then frozen in liquid nitrogen-cooled isopentane. Sections
of 14 μm were prepared on a cryostat. Primary cultures
of NSCs (described above) were fixed with 2 % PFA for
30 min and subjected to immunostaining.
For PACAP and PAC1R staining, sections were pretreated
with 10 mM citrate for 30 min at 80 °C. For BrdU staining,
sections were pretreated with 2 N HCl for 30 min at 37 °C and
then incubated in 5 % NHS/0.1 % Tween 20 in PBS (PBST).
Tissue sections were washed several times with PBST and
then incubated in 5 % NHS/PBST for 1 h. Subsequently, the
sections were incubated overnight with primary antibodies.
The sections were then rinsed with PBST and incubated with
appropriate secondary antibodies for 2 h. Primary and second-
ary antibodies are listed in Table 1.
For single immunostaining, in addition to the pretreatment
described above, sections were pretreated with 0.3 % H2O2.
Sections were visualized using avidin-biotin complex/
diaminobenzidine as the chromogen (Vector Laboratories,
Burlingame, CA). Single immunostaining was detected using
a microscope (AX70, Olympus, Tokyo, Japan).
For double immunostaining, fluorescently labeled antibod-
ies were used and some sections were counterstained with 4,6-
diamidine-2-phenylindole dihydrochloride (DAPI; 1:10,000;
Roche, Mannheim, Germany). Fluorescence was detected
using an Axio Imager optical sectioning microscope with
ApoTome (Zeiss, Oberkochen, Germany) or a confocal mi-
croscope (A1, Nikon, Japan) for Fig. 1a.
BrdU-positive cells in mice were manually counted in
both SGZs along the superior and inferior blades of the
dentate gyrus. The experiment comparing wild-type and
PACAP-deficient mice was performed by randomly
choosing 22–45 sections from three to six mice for each
day after ischemia. BrdU-positive cells/section were cal-
culated by the average of the sum of the left and right
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BrdU-positive cells. For the experiment comparing BrdU-
positive cells/SGZ in vehicle and PACAP treatments, se-
rial sections including the hippocampus were prepared
from eight to ten mice, and all BrdU-positive cells in
the SGZ were counted in each animal.
Real-Time PCR
Real-time polymerase chain reaction (PCR) was performed
according to our previous report (Nakamachi et al. 2012). In
brief, brains were removed from intact wild-type mice (0 h)
and wild-type mice that underwent global ischemia at 6 h,
12 h, 1, 3, 7, 14, 28, and 56 days. Hippocampi of both hemi-
spheres were immediately separated on ice and then snap fro-
zen in liquid nitrogen. The samples were stored at −80 °C until
analysis. PACAP mRNA in tissues was quantified by real-
time PCR using SYBR Premix Ex Taq II reagent (Takara
Bio. Inc., Shiga, Japan) with an ABI PRISM 7900 sequence
detection system (Applied Biosystems, Lincoln, CA). Total
RNAwas isolated from the tissue and reverse transcribed into
cDNA using a PrimeScript RT reagent Kit (Takara Bio, Inc.).
PCR amplification of cDNAwith primers specific for PACAP
and β-actin as a housekeeping gene was carried out. The
primer sequences are shown in Table 2. Relative gene expres-
sion was calculated using the comparative ΔCt method in
which gene expression levels were compared with Ct values
of the housekeeping gene. Mouse PACAP mRNA levels were
subsequently normalized to the percentage values obtained
from intact control groups (considered as 100 %).
Statistical Analysis
Data are expressed as the mean ± standard error of the mean
(SEM). Statistical comparisons were made by nonrepeated
measures analysis of variance after the Tukey–Kramer post
hoc test. Data for comparison of two groups were analyzed
by two-tailed Student’s t test. Statistical significance was ac-
cepted at p < 0.05.
Results
Double Immunostaining of PAC1R and Nestin
in the Adult Mouse SGZ and Cultured NSCs
Double immunostaining of PAC1R and nestin was performed
to confirm the presence of PAC1R in NSCs. PAC1R and
nestin were colocalized in the adult mouse SGZ of the hippo-
campus (Fig. 1a). Similar results were also obtained by double
immunostaining of PAC1R and nestin in cultured NSCs
(Fig. 1b).
BrdU-Positive Proliferative Cells Are Increased
in the Mouse SGZ After PACAPAdministration
To evaluate the effect of exogenous PACAP, we examined
proliferative cells in the adult mouse hippocampus after
PACAP or vehicle treatment using BrdU labeling.
PACAP38 (480 pmol/kg/day) or the vehicle only were
Table 1 Antibodies used for immunostaining
Antibody Target/description Host Clone Company Catalog number Dilution factor
PAC1R PACAP-specific receptor Rabbit Polyclonal Produced by our laboratory 400
Nestin Neural stem cells Mouse Rat401 BD Pharmingen 556309 1000
BrdU Proliferative cells Rat BU1/75 Oxford Biotechnology OBT0030 2000
SOX2 Stem cells Rabbit Polyclonal Abcam Ab15830 200
IBA1 Microglia Rabbit Polyclonal Wako 019-19741 2000
S100β Astrocytes Rabbit Polyclonal Sigma S2644 2000
NeuN Mature neurons Mouse A60 EMD Millipore MAB377 1000
PACAP PACAP Rabbit Polyclonal Peninsula Laboratories T-4473 200
Tuj1 Immature neurons Mouse Tuj1 BioLegend 801201 1000
GFAP Astrocytes, some neural stem cells Mouse G-A-5 Sigma G3893 1000
Rabbit IgG Alexa 488- or 546-labeled secondary
antibodies
Goat Polyclonal Molecular Probes A-11034, A-11035 500
Rabbit IgG Biotin-labeled secondary antibody Goat Polyclonal Santa Cruz sc-2040 200
Mouse IgG Alexa 488- or 546-labeled secondary
antibodies
Goat Polyclonal Molecular Probes A-11029, A-11030 500
Rat IgG Biotin-labeled secondary antibody Rabbit Polyclonal Vector Laboratories BA-4001 200
Rat IgG Alexa 488-labeled secondary antibody Goat Polyclonal Molecular Probes A-11006 500
PACAP pituitary adenylate cyclase-activating polypeptide, BrdU bromodeoxyuridine, SOX2 sex-determining region Y-box 2, IBA1 ionized calcium-
binding adapter molecule 1, S100β S100 calcium-binding proteinβ,NeuN neuronal nuclei, Tuj1 neuron-specificβIII tubulin,GFAP glial fibrillary acidic
protein
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injected into the lateral ventricle of C57/BL6 wild-type mice
continuously for 7 days. BrdU was injected at a dose of
50 mg/kg six times before sacrifice on day 7. BrdU immuno-
histochemistry showed greater numbers of BrdU-positive
cells in PACAP-treated mice than in vehicle-treated mice
(Fig. 2a). During this time, BrdU-positive cells were mainly
observed in the SGZ of the hippocampus. BrdU-positive cells/
SGZ were significantly (p < 0.05) higher in PACAP-treated
mice than in vehicle-treated mice (Fig. 2b).
BrdU-Positive Cells Do Not Increase in the Hippocampus
of PACAP-Deficient Mice After Global Ischemia
Cerebral ischemia is known to cause neuronal degenera-
tion in the hippocampus. A recent study showed that
NSCs proliferate after ischemia and are involved in func-
tional recovery (Christian et al. 2014). To investigate the
contribution of endogenous PACAP to increasing NSCs,
we compared the numbers of BrdU-positive cells in wild-
type and PACAP-deficient (PACAP+/−) mice after global
ischemia. We used PACAP+/− mice because PACAP−/−
pups had a high mortality rate. PACAP expression in
PACAP+/− mice was reported to be greatly decreased
(about 70 % reduction) compared with wild-type mice
(Hashimoto et al. 2001). C57/BL6 wild-type and C57/
BL6 PACAP-deficient mice underwent global ischemia
as described in the BMaterials and Methods.^ Mice were
sacrificed on days 0, 1, 3, 7, 14, 28, and 56. BrdU
(300 mg/kg) was injected at 3 h prior to sacrifice. BrdU-
positive cells/section were significantly decreased in
PACAP-deficient mice compared with wild-type mice on
days 3 and 7 (Fig. 3a, b). No significant increase was
observed in PACAP-deficient mice after global ischemia
throughout the experiment (Fig. 3b).
Identification of BrdU-Positive Cells After Global
Ischemia
We confirmed an increase in BrdU-positive cells in the
SGZ after global ischemia in wild-type mice, the highest
of which was at day 7. To examine which cells were
proliferating, we stained for BrdU and several neural
Fig. 1 PAC1R is expressed in
NSCs. a Double-immunostained
sections of the SGZ in the adult
mouse hippocampus. PAC1R
(red) was colocalized with nestin
(green), a marker of NSCs.
Sections were counterstained with
DAPI (blue). b Double
immunostaining showed PAC1R
(red) colocalized with nestin
(green) in cultured NSCs. Cell
nuclei were stained with DAPI
(blue)
Table 2 Primers used for real-time polymerase chain reaction
Name Official symbol Species Forward (5′–3′) Reverse (5′–3′) Product size (bp)
PACAP Adcyap1 Mouse AACCCGCTGCAAGACTTCTATGAC TTAAGGATTTCGTGGGCGACA 125
β-Actin Actb Mouse CATCCGTAAAGACCTCTATGCCAAC ATGGAGCCACCGATCCACA 171
PACAP pituitary adenylate cyclase-activating polypeptide
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markers at day 7 after global ischemia in wild-type mice.
BrdU was colocalized with the NSC marker SOX2
(Fig. 4a). No coexpression was observed with the
microglial marker IBA1 or astrocyte marker S100β
(Fig. 4a). Next, we investigated the fate of BrdU-
positive cells after a longer period of time. BrdU was
injected into wild-type mice at day 7 after global ische-
mia, and then, samples were collected at day 28. Double
immunostaining was performed for BrdU and NeuN.
BrdU was colocalized with NeuN at day 28 (Fig. 4b).
Fig. 2 PACAP treatment increases BrdU-positive proliferative cells in
the hippocampal SGZ of adult mice. a BrdU-immunostained
hippocampal SGZ after PACAP or vehicle administration. BrdU-
immunopositive cells were increased after PACAP administration. b
Quantitative data of BrdU-positive cells in the hippocampal SGZ after
PACAP or vehicle treatment. BrdU-positive cells in the SGZ were
significantly increased in the PACAP-treated group compared with the
vehicle-treated group. Bars represent the means ± standard error of the
mean (SEM). n = 8, vehicle group; n = 10, PACAP group.*P < 0.05
Fig. 3 BrdU-positive cells do not
increase after global ischemia in
PACAP knockout (KO) mice. a
BrdU-immunostained
hippocampus before or at 7 days
after global ischemia in wild-type
and PACAP KO mice. BrdU
staining increased after ischemia
in wild-type mice but not in
PACAP KO mice. b Quantitative
data of BrdU-positive cells in the
hippocampal SGZ after global
ischemia in wild-type and
PACAP KO mice over a time
course. BrdU-positive cells/
section were significantly
increased on days 3 and 7 in wild-
type mice, while no such increase
was observed in PACAP KO
mice throughout the experiment.
Bars represent the means ± SEM.
n = 22–45 per group.*P < 0.05
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These data suggest that BrdU-labeled cells at day 7 after
ischemia were NSCs and had subsequently differentiated
into mature neurons.
Localization of PACAPAfter Global Ischemia
PACAP immunostaining at day 7 showed an increase of
PACAP in the SGZ and hilus of the hippocampus after
global ischemia (Fig. 5a). We also assessed the mRNA
expression of PACAP by real-time PCR. Consistent with
our other results, the mRNA expression of PACAP was
significantly increased and the highest at day 7 after glob-
al ischemia (Fig. 5b). Next, we performed double immu-
nostaining of PACAP and neuronal markers and deter-
mined the localization of PACAP in the SGZ and hilus.
PACAP was coexpressed with nestin in the SGZ but not
with NeuN or Tuj1. In the hilus, PACAP was coexpressed
with NeuN, but not with Tuj1 or glial fibrillary acidic
protein (GFAP) (Fig. 5c). These data suggest that
PACAP was secreted from NSCs in the SGZ and mature
neurons in the hilus.
Discussion
In the present study, we demonstrated the effects of exogenous
and endogenous PACAP in NSCs of the SGZ in the hippo-
campus. Among the three receptors that mediate PACAP ac-
tions, PACAP binds to PAC1R specifically with high affinity
(Arimura 1998). This receptor is distributed highly in neuro-
genic areas such as the SVZ and hippocampus (Vaudry et al.
2009), and studies suggest the contribution of PACAP to pro-
liferation and differentiation of NSCs (Nakamachi et al. 2011;
Watanabe et al. 2007). PACAP affects NSCs via PAC1R in
these areas. Therefore, we first examined the localization of
PAC1R in the SGZ and cultured NSCs by performing double
immunostaining of PAC1R and the NSC marker nestin.
Immunoreactivities of PAC1R and nestin were colocalized
in both cultured NSCs and NSCs in the SGZ (Fig. 1a, b).
These results suggest that NSCs in the SGZ of adult mice
express PAC1R, indicating that PACAP has a role in NSCs.
Our previous study reported strong expression of PAC1R in
nestin- and GFAP-positive adult NSCs in the SVZ of the lat-
eral ventricle (Matsuno et al. 2008). Another group also
showed expression of PAC1R in the adult neural germinal
Fig. 4 Characterization of BrdU-
positive cells in the hippocampus
of wild-type mice at days 7 and 28
after global ischemia. a Double-
immunostained brain sections at
day 7 after global ischemia. BrdU
colocalized with the NSC marker
SOX2. No coexpression was
observed with the microglial
marker IBA1 or astrocyte marker
S100β. b Double
immunostaining at day 28 after
global ischemia. BrdU was
colocalized with the mature
neuronal marker NeuN
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area such as the SVZ and SGZ (Ohta et al. 2006). Here, we
first identified that cells expressing PAC1R in the adult SGZ
of the hippocampus as nestin-positive NSCs.
We then examined the effect of PACAP in the SGZ. First,
to evaluate the effect of exogenous PACAP, we examined
proliferative cells in the adult mouse hippocampus after
PACAP or vehicle injection into the lateral ventricle. BrdU
immunohistochemistry showed greater numbers of BrdU-
positive cells in PACAP-treated mice than in vehicle-treated
mice, which were mainly in the SGZ (Fig. 2a, b). This result
suggests that exogenous PACAP increases the proliferation of
NSCs in the SGZ. A previous study reported that administra-
tion of a high dose of PACAP (approximately 61 nmol/kg/
day) increases BrdU-positive cells in the SGZ (Ohta et al.
2006). A high concentration of PACAP can activate
VPAC2R and result in vasodilation, tachycardia, and water
retention (Farnham et al. 2011; Lamine et al. 2015; Tsutsumi
et al. 2002; Warren et al. 1992). These effects would limit the
use of PACAP as a neuroprotective drug. Here, we found that
a relatively low dose of PACAP (480 pmol/kg/day) increased
BrdU-positive cells in the SGZ. These data indicate not only
that PACAP is biologically important for NSCs but also po-
tentially useful for treatment of neurodegenerative diseases.
Next, to evaluate the effect of PACAP in NSCs after neuro-
nal damage, we compared wild-type and PACAP+/−mice in a
global ischemia model. Increased hippocampal neurogenesis is
known to occur following cerebral ischemia (Liu et al. 1998).
We hypothesized that PACAP plays a role in this process by
increasing cell numbers after cerebral ischemia in the hippo-
campus. To test this hypothesis, we performed BrdU immuno-
staining after global ischemia in the SGZ of the two groups.
PACAP+/−mice showed significantly less BrdU-positive cells
in the SGZ after global ischemia comparedwith wild-typemice
(Fig. 3a, b). This result suggests that endogenous PACAP plays
an important role in increasing cell numbers in the SGZ after
global ischemia. While growth factors and inflammation mod-
ulators, such as brain-derived neurotrophic factor and matrix
metalloproteinases, have been reported to play important roles
in neurogenesis after stoke (Barkho and Zhao 2011), PACAP is
also considered to be crucial for stoke-induced neurogenesis.
Interestingly, BrdU-positive cells did not differ between the
two groups before global ischemia (Fig. 3b, day 0).
Endogenous PACAP did not appear to be involved in the pro-
liferation of cells in the SGZ under normal conditions.
However, PACAP may be needed during conditions that re-
quire stimulation of proliferation. A study comparing wild-type
and PACAP-deficient mice under standard and enriched envi-
ronment conditions obtained similar findings indicating that the
survival of newly divided cells under enriched conditions in-
creases in wild-type mice but does not differ under standard
conditions (Ago et al. 2011).
We next investigated the fate of BrdU-positive cells that
increased after global ischemia in the SGZ. Although hippo-
campal neurogenesis is known to occur in the SGZ, and NSCs
are the prominent proliferative cells in the SGZ, astrocytes and
microglia can also be activated and proliferate after stroke. To
verify that the cells proliferating after global ischemia were
NSCs, we performed double immunohistochemistry. At day 7
after global ischemia, BrdU-positive cells colocalized with the
NSC marker SOX2 (Fig. 4a). At day 28 after global ischemia,
the cells labeled with BrdU at day 7 were immunopositive for
the mature neuronal marker NeuN (Fig. 4b). These results
Fig. 5 PACAP expression and localization at day 7 after global ischemia.
a PACAP-immunopositive cells in the hippocampus at day 7 after global
ischemia. PACAP immunoreactivity was increased after global ischemia
in the SGZ and hilus. b PACAP mRNA expression in the hippocampus.
Real-time RT-PCR showed a significant increase in the mRNA
expression of PACAP at day 7 after ischemia. c PACAP
immunoreactivity was colocalized with nestin but not NeuN or Tuj1 in
the SGZ. In the hilus, PACAP immunoreactivity was colocalized with
NeuN but not Tuj1 or GFAP
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suggest that NSCs increased in the SGZ after global ischemia
and then differentiated into mature neurons. These results are
consistent with past studies suggesting that global ischemia
stimulates cell proliferation in the SGZ by performing BrdU
injection after global ischemia (Kawai et al. 2004; Yagita et al.
2001). On the other hand, although NSCs proliferate after glob-
al ischemia, many of these new cells were reported to not sur-
vive (Yagita et al. 2001). In our study, cells that survived at day
28 had differentiated into neurons (Fig. 4b). Another study also
suggested that newly generated cells can mature into functional
neurons after adult hippocampal neurogenesis (van Praag et al.
2002). PACAP promoted the proliferation of NSCs in the SGZ,
which differentiated into neurons. This finding indicates the
potential of PACAP as a factor that could be useful for neural
repair and functional improvement after neuronal damage.
Promoting the survival of proliferating NSCs should be a chal-
lenge to consider in future studies.
Finally, we performed immunohistostaining and real-
time PCR to determine the source of PACAP after global
ischemia. Real-time PCR showed that PACAP mRNA
levels were highest at day 7 after global ischemia
(Fig. 5b). Unexpectedly, PACAP mRNA levels 3 days
after ischemia was not upregulated while BrdU-positive
cells were significantly increased at this time. We consider
that not only the expression of PACAP but that of PAC1R
in NSCs could be upregulated after stroke. This hypothe-
sis could be supported by our previous study that showed
the expression of PAC1R was upregulated after traumatic
brain injury (Morikawa et al. 2009). PACAP immuno-
staining revealed that PACAP-positive cells increased in
the SGZ and hilus of the hippocampus after global ische-
mia (Fig. 5a). Double immunostaining showed that
PACAP in the SGZ colocalized with nestin, but not with
the mature neural marker NeuN or immature neural mark-
er Tuj1 (Fig. 5c). During this time, PACAP in the hilus
was colocalized with NeuN but not Tuj1 or the astrocyte
marker GFAP. These results suggest that NSCs in the SGZ
and neurons in the hilus could be the cells producing
PACAP after global ischemia, which are supposedly re-
sponsible for increasing NSCs in the SGZ in an autocrine/
paracrine manner.
In conclusion, PACAP is an important neuropeptide that
contributes to increasing NSCs in the SGZ of the hippocam-
pus. This increase can lead to hippocampal neurogenesis and
may regenerate neurons that are damaged after neurodegener-
ative diseases such as cerebral ischemia. Future studies ad-
dressing the molecular basis and pathophysiological implica-
tions of PACAP-associated responses of NSCsmay contribute
to the development of treatments for neural disorders.
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